Subscribe to RSS
DOI: 10.1055/s-2001-14096
© Georg Thieme Verlag Stuttgart · New York
Prädiktion und Prävention des Typ-1-Diabetes
Prediction and prevention of type 1 diabetesPublication History
Publication Date:
31 December 2001 (online)

Die klinische Manifestation des Typ-1-Diabetes mellitus ist der Endpunkt einer Entzündung und autoimmunen Zerstörung der insulinproduzierenden Betazellen des Pankreas. Bereits viele Jahre vor Ausbruch der Erkrankung treten bei Betroffenen Insel-Autoantikörper auf, die in Venen- oder Kapillarblut detektierbar sind. Dies ermöglicht eine frühzeitige Diagnose der Autoimmunerkrankung noch vor dem Auftreten von klinischen Symptomen der Hyperglykämie.
In der vorliegenden Übersicht werden Strategien der Früherkennung diskutiert und Empfehlungen zum Einsatz von immunologischen, genetischen bzw. metabolischen Markern zur Risikoabschätzung des Typ-1-Diabetes gegeben. Des weiteren werden laufende Studien zur Prävention des Typ-1-Diabetes vorgestellt.
Literatur
- 1 Akerblom H J, Virtanen S M, Hämäläinen. et al .Modulation of the appearance of diabetes 
            associated autoantibodies in the nutritional prevention of type 
            1 diabetes (TRIGR) project. Abstract book 4th 
            immunology of Diabetes Society Congress 1999: 123 
            Reference Ris Wihthout Link
- 2 
            Atkinson M A, MacLaren N K. 
            The pathogenisis 
            of insulin-dependent diabetes mellitus. 
            New England Journal 
            of Medicine. 
            1994; 
            331 
            1428-1436 
            
            Reference Ris Wihthout Link
- 3 
            Bingley P J, Bonifacio E, Williams A J, Genovese S, Bottazzo G F, Gale E A. 
            Prediction of 
            IDDM in the general population: strategies based on combinations 
            of autoantibody markers. 
            Diabetes. 
            1997; 
            46 
            1701-1710 
            
            Reference Ris Wihthout Link
- 4 
            Bingley P J, Bonifacio E, Ziegler A G, Schatz D A, Atkinson M A, Eisenbarth G S. on behalf of 
            the Immunology of Diabetes Society .
            Proposed Guidelines 
            on Screening for Risk of Type 1 Diabetes. 
            Diabetes Care. 
            2001; 
            24 
            398 
            
            Reference Ris Wihthout Link
- 5 
            Christie M R, Roll U, Payton M A, Hatfield E C, Ziegler A G. 
            Validity 
            of screening for individuals at risk for type I diabetes by combined 
            analysis of antibodies to recombinant proteins. 
            Diabetes 
            Care. 
            1997; 
            20 
            965-970 
            
            Reference Ris Wihthout Link
- 6 
            Dittler J, Seidel D, Schenker M, Ziegler A G. 
            GADIA2-combi 
            determination as first-line screening for improved prediction of 
            type 1 diabetes in relatives. 
            Diabetes. 
            1998; 
            47 
            592-597 
            
            Reference Ris Wihthout Link
- 7 
            Feeney S J, Myers M A, Mackay I R, Zimmet P Z, Howard N, Verge C F, Rowley M J. 
            Evaluation 
            of ICA512As in combination with other islet cell autoantibodies 
            at the onset of IDDM. 
            Diabetes Care. 
            1997; 
            20 
            1403-7 
            
            Reference Ris Wihthout Link
- 8 
            Füchtenbusch M, Ferber K, Standl E, Ziegler A G. 
            Prediction 
            of type 1 diabetes postpartum in patients with gestational diabetes 
            mellitus by combined islet cell autoantibody screening: a prospective 
            multicenter study. 
            Diabetes. 
            1997; 
            46 
            1459-1467 
            
            Reference Ris Wihthout Link
- 9 
            Füchtenbusch M, Rabl W, Grassl B, Bachmann W, Standl E, Ziegler A G. 
            Delay 
            of type I diabetes in high risk, first degree relatives by parenteral antigen 
            administration: The Schwabing Insulin Prophylaxis Pilot Trial. 
            Diabetologia. 
            1998; 
            41 
            536-541 
            
            Reference Ris Wihthout Link
- 10 
            Ido Y, Vindigni A, Chang K. et al .
            Prevention 
            of vascular and neural dysfunction in diabetic rats by C-peptide. 
            Science. 
            1997; 
            277 
            563-566 
            
            Reference Ris Wihthout Link
- 11 
            Lohmann T, Seissler J, Verlohren H J, Schroder S, Rotger J, Dahn K, Morgenthaler N, Scherbaum W A. 
            Distinct 
            genetic and immunological features in patients with onset of IDDM 
            before and after age 40. 
            Diabetes Care. 
            1997; 
            20 
            524-529 
            
            Reference Ris Wihthout Link
- 12 
            Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R. 
            Prevention of autoimmune 
            diabetes in NOD mice by 1,25 dihydroxyvitamin D3. 
            Diabetologia. 
            1994; 
            37 
            552-558 
            
            Reference Ris Wihthout Link
- 13 
            Rewers M, Bugawan T L, Norris J M, Blair A, Beaty B, Hoffman M, McDuffie R S Jr, Hamman R F, Klingensmith G, Eisenbarth G S, Erlich H A. 
            Newborn screening 
            for HLA markers associated with IDDM: diabetes autoimmunity study 
            in the young (DAISY). 
            Diabetologia. 
            1996; 
            39 
            807-812 
            
            Reference Ris Wihthout Link
- 14 
            Roll U, Ziegler A G. 
            Combined 
            antibody screening for improved prediction of IDDM - Modern 
            strategies. 
            Exp Clin Endocrinol Diabetes. 
            1997; 
            105 
            1-14 
            
            Reference Ris Wihthout Link
- 15 
            Schatz D, Krischer J, Horne G, Riley W, Spillar R, Silverstein J, Winter W, Muir A, Drovanesian D, Shah S, Malone J, MacLaren N. 
            Islet 
            cell antibodies predict insulin-dependent diabetes in United States 
            school age children as powerfully as in unaffected relatives. 
            J 
            Clin Invest. 
            1994; 
            93 
            2403-2407 
            
            Reference Ris Wihthout Link
- 16 
            Schenker M, Hummel M, Ferber K, Walter M, Keller E, Albert E D, Janka H U, Kastendiek C, Sorger M, Louwen F, Ziegler A G. 
            Early 
            expression and high prevalence of islet autoantibodies for DR3/4 
            heterozygous and DR4/4 homozygous offspring of parents 
            with Type I diabetes: The German BABYDIAB study. 
            Diabetologia. 
            1999; 
            42 
            671-677 
            
            Reference Ris Wihthout Link
- 17 
            Schloot N C, Pozzilli P, Mandrup-Poulsen T. 
            Immune 
            markers for monitoring the progression of autoimmune disease. 
            Diabetes 
            Metab Res Rev. 
            1999; 
            15 
            141-145 
            
            Reference Ris Wihthout Link
- 18 
            Seissler J, Hering B, Richter W, Gluck M, Yassin N, Bretzel R G, Boehm B O, Federlin K, Scherbaum W A. 
            Antibodies 
            to the M(r) 64,000 (64K) protein in islet cell antibody positive 
            non-diabetic individuals indicate high risk for impaired beta-cell 
            function. 
            Diabetologia. 
            1992; 
            35 
            550-554 
            
            Reference Ris Wihthout Link
- 19 
            Strebelow M, Schlosser M, Ziegler B, Rjasanowski I, Ziegler M. 
            Karlsburg Type 
            I diabetes risk study of a general population: frequencies and interactions 
            of the four major Type I diabetes-associated autoantibodies studied 
            in 9419 schoolchildren. 
            Diabetologia. 
            1999; 
            42 
            661-670 
            
            Reference Ris Wihthout Link
- 20 
            The Eurodiab Substudy 2 Study 
            Group .
            Vitamin D supplement in early childhood and 
            risk for Type I (insulin-dependent) diabetes mellitus. 
            Diabetologia. 
            1999; 
            42 
            51-54 
            
            Reference Ris Wihthout Link
- 21 
            Verge C F, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Chase H P, Eisenbarth G S. 
            Number 
            of autoantibodies (against insulin, GAD or ICA512/IA2) 
            rather than particular autoantibody specificities determines risk 
            of type I diabetes. 
            J Autoimmun. 
            1996; 
            9 
            379-383 
            
            Reference Ris Wihthout Link
- 22 
            Verge C F, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson R A, Chase H P, Eisenbarth G S. 
            Prediction 
            of type I diabetes in first-degree relatives using a combination 
            of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. 
            Diabetes. 
            1996; 
            45 
            926-933 
            
            Reference Ris Wihthout Link
- 23 
            Wahren J, Johansson B L. 
            Ernst-Friedrich-Pfeiffer 
            Memorial Lecture. New aspects of C-peptide physiology. 
            Horm 
            Metab Res. 
            1998; 
            30 
            A2-5 
            
            Reference Ris Wihthout Link
- 24 
            Ziegler A G, Hummel M, Schenker M, Bonifacio E. 
            Autoantibody Appearance 
            and Risk for the Development of Childhood Diabetes in Offspring of 
            Parents with Type 1 Diabetes: The German BABY-DIAB Study. 
            Diabetes. 
            1999; 
            48 
            460-468 
            
            Reference Ris Wihthout Link
Korrespondenz
Prof. Dr. med. Anette-G. Ziegler
         Institut für Diabetesforschung und 3. 
         Med. Abteilung, Krankenhaus München-Schwabing
         
         Kölner Platz 1
         
         80804 München
         
         Phone: 089/30793114
         
         Fax: 089/3081733
         
         Email: prevent.diabetes@lrz.uni-muenchen.de
         
         
 
     
      
    